Abstract:ID 92941 Poster Board 546 Ebola virus (EBOV), a negative-sense RNA virus, is zoonotic pathogen that causes severe hemorrhagic fever with high case fatality rates in humans. EBOV disease outbreaks have been occurring since 1976. The largest outbreaks took place in West African in 2014 and resulted in over 28,000 cases and 11,000 deaths. There have been advances in the development of EBOV vaccines and monoclonal antibodies. However, no antiviral drugs are yet approved, especially for the treatment of pan-filovirus infections. EBOV transcription requires viral VP30 and VP35 proteins, which, according to our recently conducted global proteomic study (1), are phosphorylated in the EBOV virions. Phosphorylation of VP35 on Thr-210 regulated EBOV transcriptional activity and VP35 interaction with EBOV-NP (1). Host protein phosphatases, PP1 and PP2A were shown to facilitate EBOV transcription and replication (2,3). Our unpublished observations indicate that NP E619K mutant binds stronger to PP1 and that binding compromises formation of EBOV capsid. Thus, targeting PP1 might be a valuable approach for EBOV inhibition. Recent high throughout screen conducted in Mathieu Bollen's laboratory at KULeuven identified several gold-containing compounds including FDA approved Auranofin among 400,000 compounds that were screened for PP1 as target. Here we tested the effect of Auranofin and chloro-gold compounds on EBOV transcription and replication and NP interaction with VP35. Auranofin inhibited EBOV minigenome (IC 50 = 0.5 μM) and also potently inhibited EBOV and MARV replication in Vero E6 cells at submicromolar concentrations. Compared to chloro-gold compound, Auranofin showed at least 10-times better efficacy and also less toxicity. To determine the mechanism of Auranofin action, we investigated its effect on the NP-VP35 and NP-NP interactions using split NanoBiT assay. Auranofin potently inhibited NP binding to VP35 in split NanoBiT (IC 50 = 3 μM) comparing to chloro-gold (IC 50 = 12 μM). Auranofin demonstrated low cytotoxicity (IC 50 >300 μM) in 293T cells that were used for the split NanoBiT. Auranofin also showed potent inhibition of NP-NP interaction in split NanoBiT (IC 50 = 1 μM) comparing to chloro-gold (IC 50 = 3 μM). Taken together, our study suggests that Auranofin may serve as EBOV inhibitor by targeting EBOV NP-VP35 and NP-NP interactions. As Auranofin is approved for human use for rheumatoid arthritis, it is feasibly can be further tested as an inhibitor for EBOV and MARV infections References Ivanov A, ... Bukreyev A, Nekhai S. 2020. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cell Mol Life Sci 77:2579–2603. Ilinykh PA, ... Nekhai S, Bukreyev A. 2014. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723–38. Kruse T, ... Nilsson J, Becker S. 2018. The Ebola Virus Nucleoprotein Recruits the Host PP2A-B56 Phosphatase to Activate Transcriptional Support Activity of VP30. Mol Cell 69:136–145 e6 Acknowledgements: We thank Dr. Mathieu Bollen for sharing screening data, Dr. Elke Mühlberger for providing the EBOV minigenome, and Dr. Yoshihiro Kawaoka for providing the plasmids expressing EBOV NP, VP35, L, VP30, and the T7 polymerase. This project was supported by the NIH Research Grants U19AI109664, 5U54MD007597, 2R01HL125005 and P30AI117970

A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus

Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies

Genome-wide CRISPR/Cas9 screen identifies SLC39A9 and PIK3C3 as crucial entry factors for Ebola virus infection

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamics

Fragment screening targeting Ebola virus nucleoprotein C-terminal domain identifies lead candidates

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry

Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses

An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening

A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus

A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

Auranofin Inhibits Ebola Virus Replication by Targeting NP-VP35 and NP-NP Interactions

Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein

Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein

Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds

Therapeutic strategies to target the Ebola virus life cycle

Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation